Orexigen Therapeutics Launches Next Stage of a Dynamic Campaign to Educate Consumers About Contrave®

SAN DIEGO, Sept. 26, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced today the launch of the next stage of "Brains Behind Weight Loss," the Company's national direct-to-consumer advertising campaign for Contrave® (naltrexone HCl/bupropion HCl extended release...